Long-term efficacy and safety of PEGylated recombinant human growth hormone in treating Chinese children with growth hormone deficiency: a 5-year retrospective study
Administering PEG-rhGH at a dosage of 0.2 mg/kg/week proved both effective and well-tolerated in treating prepubertal children with GHD. This regimen also demonstrated positive impacts on lipid metabolism over an extended treatment period.
Authors
- Zulin Liu
- Shaofen Lin (ORCID: https://orcid.org/0009-0002-0974-9205)
- Lele Hou (ORCID: https://orcid.org/0000-0003-0862-4785)
- Siqi Huang (ORCID: https://orcid.org/0000-0002-6216-8648)
- Lina Zhang (ORCID: https://orcid.org/0000-0002-3327-1160)
- Hui Ou
- Huilian Dai
- Liyang Liang (ORCID: https://orcid.org/0000-0002-4112-3520)
- Zhe Meng (ORCID: https://orcid.org/0009-0005-0523-7968)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
Publication Details
- Journal
- Journal of Pediatric Endocrinology and Metabolism
- Published
- 2024-08-22
- DOI
- https://doi.org/10.1515/jpem-2024-0189
- Citations
- 4
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 1.43